

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/78689 A2

(51) International Patent Classification⁷: **A61K 9/51, 9/12**

(21) International Application Number: **PCT/GB01/01752**

(22) International Filing Date: **18 April 2001 (18.04.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
0009773.3 19 April 2000 (19.04.2000) **GB**

(71) Applicant (for all designated States except US): **UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED [GB/GB]; P.O. Box 497, Cardiff CF1 3XR (GB).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DICKINSON, Paul, Alfred [GB/GB]; 6 Turnberry Close, Tytherington, Macclesfield SK10 2TQ (GB). KELLAWAY, Ian, Walter [GB/GB]; 1 Cyncoed Avenue, Cardiff CF23 6ST (GB). HOWELLS, Stephen, Wyn [GB/GB]; 61 Pentre Street, Grangetown, Cardiff CF11 6QX (GB).**

(74) Agents: **HOWARD, Paul, Nicholas et al.; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).**

(81) Designated States (*national*): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**


(84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **PARTICULATE COMPOSITION**



(57) Abstract: Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with the micelles of surfactant material. At least the dispersed phase is quenched to a solid state and the continuous phase and solvent are removed to produce the nanoparticles. The nanoparticles can be incorporated in an aerosol composition suitable for deep lung delivery by means of a metered dose inhaler.

BEST AVAILABLE COPY

WO 01/78689 A2

PARTICULATE COMPOSITION

The present invention relates to a particulate composition and to a method for preparing a particulate composition. Particularly, but not exclusively, the present invention also relates
5 to an aerosol composition including the present particulate composition and to the use of such an aerosol composition in administering a medicament, for example, for treating a respiratory disease.

There have been a number of proposals to provide particulate compositions comprising so-
10 called nanoparticles. "Nanoparticles" are particles whose average dimension lies within the range of from 1nm to up to, but not including, 1000 nm.

EP-A-0526666 describes a process for preparing solid lipid microspheres having an average diameter lower than one micron. The process comprises forming a microemulsion
15 comprising a molten lipid, which may contain a drug, and a mixture of water and surfactant, dispersing the microemulsion in water at a temperature of between 2 and 10°C, washing the lipid microspheres obtained with water through diafiltration to remove the surfactant and any free drug, and lyophilising.

20 WO 93/00076 describes nanoparticles as a carrier system for drugs. The particles are formed from a biopolymer by desolvation, thermal denaturation, reaction with a coupling reagent and/or reaction with a compound having two or more functional groups. The drug can be loaded into or onto the spherical particle, either simultaneously with the preparation of the carrier system or sequentially, by the addition of a suspension of spherical particles
25 to an appropriate drug solution. The preparation is said optionally to comprise the addition of 0.1 to 2% of a surfactant.

EP-A-0877033 describes a reverse micelle emulsion cross-linked polymerisation reaction to produce particles up to 100 nm. The polymerized reaction product is dried to remove
30 solvent and the dried particles dispersed in an aqueous buffer. Surfactant and other toxic materials are then separated from the particles.

WO 96/25919 describes an aerosol comprising droplets of an aqueous dispersion of nanoparticles. The nanoparticles comprise beclomethazone particles having a surface modifier on the surface thereof. The beclomethazone nanoparticles can be prepared by grinding or a micro-precipitation method.

5

EP-A-0274431 describes forming a mixture of one or more surface-active agents, water and one or more physiologically active compounds and emulsifying the mixture by means of a colloid mill and/or micro fluidiser to produce a two phase coacervate composition.

- 10 It is an object of the present invention to provide a particulate composition in a dry state comprising nanoparticles which composition provides an improvement over the prior art.

It is a further object of the present invention to provide a method for preparing a particulate composition.

15

It is a further object of the present invention to provide an aerosol composition comprising the particulate composition of the present invention and an aerosol liquid propellant.

- According to a first aspect of the present invention there is provided a particulate
20 composition comprising particles, wherein the said particles:

- (a) include an active material and, with respect to the total weight of the particles, more than 2 wt% of a surfactant material;
- 25 (b) have an average diameter of more than about 1nm and less than about 1000 nm;
- (c) are spheroidal or spherical in shape; and
- 30 (d) contain no cross-linked polymer formed from a monomer or preformed polymer with a cross-linking agent and initiator.

Preferably the active material is a medicament.

According to a further aspect of the present invention there is provided an aerosol composition comprising a liquid aerosol propellant and the present particulate composition.

5

The aerosol composition can be in a form suitable for oral inhalation, nasal and/or ocular administration to a patient.

10 The surfactant material contained in the present particulate composition can determine the surface properties of the particles. In particular, the choice of surfactant material can permit the exterior surface of the particles to be tailored to a specific application.

For example, when contained in an aerosol composition the surfactant material contained in the present particulate composition can aid dispersion of the particles throughout the
15 liquid propellant.

The nanometer size or less of the present particles permits delivery in the form of an oral or nasal aerosol inhaler to the lower pulmonary tissues, including the alveoli and lower
20 airways.

The presence of the surfactant in the present particulate composition can ensure a smooth exterior surface to the particles.

25 The absence in the particles of the present particulate composition of cross-linked polymer formed using a cross-linking agent and initiator ensures the absence of any residual monomer, preformed polymer, cross-linking agent or initiator. Any such residues are inevitably present in a cross-linked polymer product formed using cross-linking agent and initiator, albeit, in small amounts, and are potentially toxic in *in vivo* applications and capable of adversely affecting the stability of the medicament.

30

The present particles preferably comprise a core material including the active material and a coating on the core material comprising the surfactant material.

Preferably the particulate composition comprises particles in which the core material is hydrophilic and is surrounded by surfactant coating. Such particulate compositions having a hydrophilic core would be particularly suitable for the production of peptide, nucleic acid and/or protein-containing particles. Some such systems may be suitable for inhalation, particularly from metered dose inhalers.

Alternatively, however, the particulate composition can comprise particles in which the core material is hydrophobic and is surrounded by surfactant coating. Such an arrangement can provide a useful vehicle for the oral delivery of lipophilic poorly soluble drugs, which can show low absorption due to their slow dissolution rate. Inclusion of such drugs in the present particulate composition with a lipophilic core can show an increased dissolution rate. Some such systems may be suitable for inhalation, particularly from metered dose inhalers.

Preferably the particles have an average diameter within the range of from about 1 nm up to less than about 1000 nm. More preferably, the particles have an average diameter within the range of from about 10 nm to about 800 nm, even more preferably within the range of from about 20 nm to about 400 nm.

For use in an aerosol composition intended for deep lung delivery of a medicament, the present particulate composition ideally comprises particles having an average diameter within the range of from about 1 nm up to less than about 1000 nm.

Throughout the present specification, by the term "average diameter" is meant the mean diameter calculated from photon spectroscopy measurement.

Preferably the particles of the present particulate composition comprise, with respect to the total weight of the particles, up to about 90 wt% surfactant material, more preferably up to about 80 wt% surfactant material, even more preferably up to about 60 wt% surfactant material. The particles preferably comprise more than about 10 wt%, more preferably more than about 20 wt%, even more preferably more than about 30 wt% surfactant material, with respect to the total weight of the particles. The actual amount of surfactant

material selected will be dependent on the particular benefits which it is desired to confer on the resultant dry particles.

The surfactant material employed can be selected from the group comprising ionic (including anionic and cationic), nonionic, zwitterionic and amphoteric surfactants and mixtures thereof. Throughout the present specification the term "surfactant" includes within its scope "emulsifier". The surfactant may also include a co-surfactant. Suitably a surfactant for use in the present invention is selected from the group comprising phospholipids; sorbitan esters (some of which are known as SPANs); poloxamers; polyoxyethylene sorbitan esters (some of which are known as TWEENS); polyoxyethylene esters (some of which are known as Brij); bile salts; sodium bis (2-ethylhexyl) sulphosuccinate (available commercially as Aerosol OT and known as AOT); and mixtures thereof. If desired, co-surfactant can be included for the surfactant selected.

A preferred surfactant for use in an aerosol composition is lecithin in combination with propan-2-ol at a weight ratio of lecithin to propan-2-ol in the range of from 1:3 to 1:10, preferably at a weight ratio of 1:3.

The present particulate composition can provide particles in a dry state, by which is meant a particulate material that feels dry to touch and flows as a powder.

Where the active material present in the particulate composition is a medicament it can be any medicament that can usefully be delivered in the form of particles having a size of from about 1 nm up to about 1000 nm.

Medicaments appropriate for delivery in the form of an aerosol composition intended for use as an inhaler include medicaments for use in the treatment and prevention of asthma and other conditions associated with reversible airways obstruction. Such medicaments either alone or in any combination can be selected from the group comprising:

- (i) salbutamol, salbutamol sulphate, mixtures thereof and physiologically acceptable salts and solvates thereof,

- (ii) terbutaline, terbutaline sulphate, mixtures thereof and physiologically acceptable salts and solvates thereof,
- (iii) beclomethasone dipropionate and physiologically acceptable solvates thereof,
- (iv) budesonide and physiologically acceptable solvates thereof,
- (v) triamcinolone acetonide and physiologically acceptable solvates thereof,
- (vi) ipratropium bromide and physiologically acceptable salts and solvates thereof,
- (vii) corticosteroid or bronchodilator, and
- (viii) leukotriene antagonists.

Other examples of particulate medicaments suitable for oral or nasal inhalation by means of the present aerosol composition include:

- (ix) peptides, proteins, nucleic acids and derivatives thereof for use in the treatment and prevention of disease states; and
- (x) insulin, calcitonin, growth hormone, lutenising hormone release hormone (LHRH), leuprolide, oxytocin and physiologically acceptable salts and solvates thereof for use in the treatment and prevention of disease states including diabetes.

Further examples of appropriate medicaments which can be formed into the present particulate compositions may additionally be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate, ketotifen or nedocromil; anti-infectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and

pentamidine; antihistamines, e.g., methapyrilene; antiinflammatories, e.g., beclomethasone dipropionate, fluticasone propionate, flunisolide, budesonide, rofleponide, mometasone furoate or triamcinolone acetonide; antitussives, e.g., noscapine; bronchodilators, e.g., albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, or (-)-4-amino-3,5-dichloro- α [[[6-[2-(2-pyridinyl)ethoxy] hexyl]methyl] benzenemethanol; diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium, tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.

15

Preferred medicaments are selected from salbutamol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.

20 Medicaments can also be delivered in combinations. Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an anti-inflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).

25

Examples of nucleic acid systems include corrective plasmid DNA (pDNA) constructs capable of expressing a therapeutic gene. Preferred nucleic acid systems are pDNA constructs whose stability and activity have been enhanced by pre-condensation with a polycationic peptide, for example, a protamine such as protamine sulphate. Suitably any
30 protamine is included at a concentration of 0.1 to 10 mg/mg, more suitably 0.8 to 2 mg/mg, with respect to the nucleic acid.

The dosage requirements for any one medicament will be those conventionally employed in, for example, inhalers. For example, where the active material is salbutamol for use in relation to asthma the inhaler is employed as required, usually 1 or 2 actuations (i.e. puffs) between 0 and 4 times per day, with a single metered dose comprising 100 micrograms of salbutamol in a volume of metered liquid propellant between 20 and 150 μ l.

If desired, the particles of the present particulate composition can include material in addition to the active material and the surfactant material. Such additional material can act as a matrix or carrier. Preferably the weight ratio of the active material to any additional material present in the particles, other than the surfactant material, lies within the range of from about 99:1 to about 1:99. More preferably such a ratio lies within the range from about 99:1 to about 20:80

Suitably, such an additional material can be a polymeric material. Preferably such a polymeric material has a molecular weight within the range of from about 250 to about 10×10^6 daltons. The presence of a polymeric material in a particulate composition can permit, for example, the sustained and controlled release of the active material once, for example, the particulate composition has been administered to a patient. Suitable examples of such polymeric materials include polyacrylic acid; chitosan; polylactic-glycolic acid; polylactic acid; albumin; and hyaluronic acid. One or more than polymeric material can be included in order to give the desired properties.

Preferably the weight ratio of the active material such as a medicament to the total amount of polymeric material present lies within the range of from about 99:1 to about 1:99, more preferably within the range of from about 99:1 to about 20:80.

A further example of an additional material that can beneficially be included in the particles comprising the present particulate composition is a sugar. The sugar may be present with or without the polymeric material.

Examples of suitable sugars include mono and/or disacharides, such as for example lactose, sucrose and trehalose. The inclusion of a sugar in the present particles can confer stability on the active material during processing and storage of the particulate

composition. Examples of active materials whose stability may be increased in the presence of sugar include nucleic acid, peptide and/or protein based drugs. Sucrose is particularly preferred for use with nucleic acids.

- 5 The weight ratio of the active material such as a medicament to any sugar present in the particles preferably lies within the range of from about 99:1 to about 1:99, more preferably from about 99:1 to about 20:80.

Further examples of additional materials that can beneficially be included in the present
10 particles, particularly when the active material is a nucleic acid and the particulate composition is intended to be used as an aerosol composition, include one or more cationic lipids as they may facilitate cellular entry of genetic material and a peptide to protect the nucleic acid. An example of a suitable cationic lipid is 1,2-dioleoyl-3-trimethylammonium propane (DOTAP).

15

Any additional material present is suitably in the form of a matrix incorporating the active material.

The present particulate composition can thus provide nanoparticles, as well as particles less
20 than 1 nm in diameter, comprising an active material, such as a drug, as a major part of the particle. Where the surfactant material is in the form of a coating, the active material in the form of, for example, a medicament can comprise 100 wt% of the core material.

In an aerosol composition according to the present invention, the liquid propellant can be
25 selected from the group comprising hydrocarbons, hydrochlorocarbons, chlorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons, fluorocarbons and mixtures thereof. Hydrofluorocarbons and fluorocarbons are preferred having regard to environmental considerations and local legislative requirements. Preferred propellants for use in an aerosol composition intended for administration to a patient include hydrofluoroalkanes
30 selected from the group comprising 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof, optionally in combination with a minor proportion of n-alkane, for example n-hexane.

Suitably the aerosol composition comprises an aerosol liquid propellant and the particulate composition at a weight ratio of liquid propellant to particulate composition within the range of from about 10,000:1 to about 25:1, more preferably within the range of from about 1,000:1 to about 100:1. Additional ingredients can be included in the aerosol composition if desired.

Preferably the aerosol composition is supplied in the form of a metered dose inhaler.

According to a further aspect of the present invention there is provided a metered dose inhaler containing the aerosol composition of the present invention.

The metered dose inhaler can be prepared by conventional manufacturing methods. For example, under the appropriate pressure the particulate composition and the liquid propellant can be admixed in bulk, dosed into the container of an inhaler and sealed under a pressure of between about 689.476 Pa (10 psig) and about 8273.712 Pa (120 psig). Alternatively, the particulate composition, if desired dispersed in an organic liquid at a preferred weight ratio of particles to organic liquid within the range of about 1:10 to about 1:100, and the liquid propellant can be dosed separately to the container of an inhaler prior to sealing under pressure. The appropriate dosing and metering valve can, in either instance, then be inserted.

According to a further aspect of the present invention the aerosol composition of the present invention is provided for use in the administration of the deep lung delivery of a medicament to a patient in need thereof.

25

Such a mode of administration can be employed to treat respiratory disease, such as for example asthma, and/or to deliver a medicament to be absorbed systemically by the patient. Examples of medicaments beneficially delivered by deep lung systemic absorption include medicaments containing a nucleic acid, a peptide and/or a protein. Medicaments for deep lung delivery containing a peptide and/or a protein, such as for example insulin, are employed to treat, for example, diabetes. Medicaments for deep lung delivery containing a nucleic acid, such as for example pDNA constructs for expression of corrective proteins, immunostimulatory proteins and enzymes, ribonucleic acids and

antisense oligonucleotides, can be employed to treat, for example, cystic fibrosis and cancer.

According to a further aspect of the present invention there is provided the use of the
5 present particulate composition in the manufacture of an aerosol composition for the lung delivery of a medicament for the treatment of, for example, respiratory disorders in a patient.

According to a further aspect of the present invention there is provided a method of
10 administering a particulate composition to a patient in need thereof comprising spraying the aerosol formed from the aerosol composition of the present invention on to or towards the area intended to receive the particulate composition.

Where the aerosol composition is in a form intended for oral or nasal application, the
15 method includes the patient inhaling the particulate composition.

According to a further aspect of the present invention there is provided a method for preparing a particulate composition comprising particles having an average diameter within the range of from about 1 nm up to less than about 1000 nm, wherein the method
20 comprises:

- (i) forming a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material;
- 25 (ii) forming a microemulsion by admixing the colloidal system of step (i) with a solution comprising an active material dissolved in a solvent, wherein the solution forms a disperse phase within the micelles of surfactant material;
- (iii) quenching at least the disperse phase to a solid state; and
- 30 (iv) removing the continuous phase and the solvent so as to yield the said particles.

Preferably step (iii) includes snap freezing the continuous phase and the disperse phase, suitably in liquid nitrogen. The continuous phase and the disperse phase can be removed by freeze-drying, otherwise known as lyophilising.

- 5 Alternatively, steps (iii) and (iv) can include quenching the disperse phase to a temperature higher than the freezing point of the continuous phase, separating, for example by centrifugation or ultrafiltration, the solidified disperse phase and the liquid continuous phase, and removing by freeze-drying the solvent from the disperse phase.
- 10 Preferably the continuous phase is an apolar liquid and the solvent is water. Suitably the apolar liquid is a hydrocarbon, preferably selected from the group comprising *iso*-octane, octane, heptane, hexane, cyclohexane and mixtures thereof. The combination of an apolar solvent and an aqueous solution contained within reverse micelles (known as L_2 micelles) of surfactant material can yield particles comprising a hydrophilic core material
- 15 containing the active material and a coating comprising the surfactant material.

Alternatively, the solvent can comprise a lipophilic compound-solubilising liquid or a liquid miscible with a lipophilic compound, and the continuous phase comprises a liquid immiscible with the solvent, such as an aqueous based phase. The combination of an

20 aqueous based continuous phase and a lipid containing disperse phase contained within normal micelles (known as L_1 micelles) can yield particles comprising a hydrophobic core material containing the active material and a coating comprising the surfactant material.

The surfactant material is suitably selected from the group comprising anionic, cationic,

25 nonionic, zwitterionic, amphoteric surfactants and mixtures thereof. As explained above, the surfactant material can be an emulsifier and the surfactant material can include a co-surfactant. Suitable and preferred surfactants are those set out above.

Preferably, the colloidal system formed in step (i) comprises a weight ratio of continuous

30 phase to surfactant material within the range of from about 10,000:1 to about 30:70, preferably within the range of from about 100:1 to about 40:60.

Preferably the solution of active material of step (ii) is at a concentration of about 2,000 to about 0.1 $\mu\text{g/g}$, more preferably about 2,000 to about 0.1 mg/g , active material in the solvent. The lower levels of concentration of the active material may be suitable for use when the active material is a nucleic acid.

5

Preferably the colloidal system of step (i) is admixed with the solution of step (ii) at a weight of colloidal system to solution within the range of from about 45:55 to about 100:1, preferably within the range of from about 60:40 to about 95:5.

- 10 The solution of step (ii) can include dissolved material additional to the said active material. The additional material can be included in the solution at a concentration of from about 2000 to about 0.1 mg/g , preferably at a concentration of from about 1500 to about 10 mg/g , with respect to the solvent. As explained above, the additional material may be suitably selected from the group comprising non-cross linked polymeric materials, sugars,
- 15 other beneficial ingredients, such as, for example, cationic lipids and peptides, and mixtures thereof. Where the active material includes a nucleic acid a polycationic peptide, such as for example protamine sulphate may suitably be included at a concentration of from about 0.1 to about 10 mg/mg , preferably 0.8 to 2 mg/mg , with respect to the nucleic acid. The nucleic acid is suitably pre-condensed with the polycationic peptide. The
- 20 cationic lipid is preferably 1,2-dioleoyl-3-trimethylammonium propane and can usefully be included when the active material is a nucleic acid.

The active material can be a medicament. The medicament can be any of those mentioned above, the solvent being selected to dissolve the medicament chosen.

25

The present method can be employed to prepare the particulate composition of the present invention. The formation of the disperse phase within the micelles of the surfactant material ensures that the finished particles have a spheroidal or spherical shape.

- 30 The particulate composition product of the present method can be employed in the preparation of the present aerosol composition, in the present use in the manufacture of an aerosol composition for lung delivery of a medicament for the treatment of, for example, a respiratory disorder in a patient, and in the present method of administering a particulate

composition to a patient in need thereof comprising spraying the aerosol formed from the present aerosol composition on to or towards the area intended to receive the particulate composition .

- 5 If desired the particles formed by the present method can be washed to reduce their content of surfactant material.

Embodiments of the present invention will now be described, by way of example only, with reference to the following examples and the accompanying drawings, wherein:

10

Figure 1 is a ternary phase diagram of an AOT/aqueous/*iso*-octane system at 20°C;

Figure 2 is a scanning electron micrograph of particles embodying the present invention;

- 15 Figure 3 is a ternary phase diagram of a lecithin:propan-2-ol 1:3/aqueous/*iso*-octane system at 20°C;

Figure 4 is a scanning electron micrograph of particles embodying the present invention;

- 20 Figure 5 is a vertical cross section of a metered dose inhaler; and

Figure 6 is a vertical cross section of the spring mechanism of the metered dose inhaler of Figure 5.

25

General experimental procedures

Construction of ternary phase diagrams

- Water-in-*iso*-octane microemulsions were produced by adding filtered distilled water to a
30 surfactant/*iso*-octane solution. Each mixture was gently agitated with a bench vortex for several seconds and then allowed to stand for 15 minutes to ensure equilibrium of the mixture. Water addition was successively repeated to determine the phase boundary between the crystal clear micellar phase and the opaque multiphase phase of the system.

Following the above experimental procedure a ternary phase diagram was constructed for the ternary system of water/sodium bis (2-ethylhexyl) sulphosuccinate/*iso*-octane at 20°C. The phase diagram is shown in Figure 1. AOT stands for Aerosol OT, which is the name
5 for a commercially available sample of sodium bis (2-ethylhexyl) sulphosuccinate. Compositions to the right of the phase boundary line shown in Figure 1 are in the form of water-in-*iso*-octane microemulsions.

Following the above experimental procedure a ternary phase diagram was constructed for
10 the ternary system of water/lecithin:propan-2-ol(1:3 by weight)/*iso*-octane. The phase diagram is shown in Figure 3. Compositions to the right of the phase boundary line shown in Figure 3 are in the form of water-in-*iso*-octane microemulsions.

Examples

15 A drug, with or without a matrix, was dissolved in water. The resulting solution was added to the selected surfactant/*iso*-octane colloidal system to give a final aqueous phase comprising 1 to 30% by weight of the total emulsion composition.

The microemulsion drug-containing composition was snap frozen by submersion in liquid
20 nitrogen.

The product was freeze-dried at -55°C to remove the *iso*-octane and the water.

Particle size analysis

25 Particles produced were dispersed in filtered *iso*-octane and sonicated for 3 minutes, transferred to a quartz cuvette and sealed to prevent *iso*-octane evaporation. The cuvette was inserted in a Coulter N4 plus to measure the size of the particles. Multimodal analysis was performed using the Coulter N4 plus standard distribution processor technology. Particle size analysis was repeated for $n > 7$.

Scanning electron microscopy (SEM) of nanoparticles

Excess surfactant was removed by washing the particles with *iso*-octane using centrifugation. The resulting nanoparticles were dried under a nitrogen stream and sputter layered with gold. Scanning electron micrographs of the resulting nanoparticles were
5 taken using a Philips XL 20 SEM.

HPLC assay of salbutamol sulphate

Salbutamol sulphate concentrations were determined using reverse phase HPLC (high pressure liquid chromatography). A C₁₈ column was employed at ambient temperature
10 with detection at 278 nm. The mobile phase consisted of a methanol:water phase at a ratio of 55:45 v/v, containing heptane sulphonic acid 1.1013 g/l and adjusted to pH 3.0 with glacial acetic acid. The mobile phase was passed through the column at a flow rate of 1 mL/min.

15 Samples were prepared using a standard solution of 600mL of ethanol made up to 1000mL with water, and containing bamethane 7 µgm L⁻¹.

Metered dose inhaler

Aerosol compositions were dosed into the metered dose inhaler illustrated in Figures 5 and
20 6. The metered dose inhaler comprises an inverted container (1) and a metering valve (2). The inverted container (1) is capable of withstanding a pressure up to 6.895×10^5 Pa (100 psig) and is closed by a closure cap (3). The metering valve (2) extends through the closure cap (3) and includes a fixed volume chamber (4), a spring mechanism (5) biased to maintain the valve closed when not being actuated and an outlet stem (6) which opens into
25 an expansion chamber (7). The container (1) and metering valve (2) are mounted by support (8) in a holder (9) which is integral with an actuator tube (10) extending at an obtuse angle away from the holder (9). As can be seen in the drawing the expansion chamber (7) opens by way of a spray jet orifice (11) into the actuator tube (10). The container (1) contains the aerosol composition (12) comprising propellant and the
30 particulate composition.

In use the container (1) is depressed relative to the holder (9) causing the chamber (4) to open to the atmosphere and the fixed volume of liquefied gas therein to expand forcing the composition into the expansion chamber (7) where the liquefied gas continues to expand and evaporate. The actuator tube (10) directs the aerosol.

5

Example 1

A microemulsion composition was prepared following the above procedure from 78% w/w *iso*-octane, 6% w/w sodium bis (2-ethylhexyl) sulposuccinate, and 16% w/w of an aqueous phase. The aqueous phase comprised, with respect to the aqueous phase, 0.06% w/w bromothymol blue and 17.17% w/w polyacrylic acid (molecular weight 2000), with the balance being water.

The size of the resulting particles was measured using the photon correlation spectroscopy technique described above employing the Coulter N4. The particles were found to be $232 \pm 58\text{nm}$, $n=7$ mean \pm sd.

The particles were also subjected to scanning electron microscopy employing the procedure described above. Figure 2 is the scanning electron micrograph of the present particles. The particles appear spherical and to have a diameter of approximately 250nm, which is in line with the data from the photon correlation spectroscopy sizing data.

Example 2

Microemulsion compositions were prepared following the above procedure for three compositions comprising *iso*-octane, lecithin:propan-2-ol(1:3 w/w) and an aqueous phase. The relative proportions of each phase and the content of the aqueous phase are given in Table I below.

25

Table I

Formulation	Iso-octane (%w/w)	Surfactant (%w/w) Lecithin: Propan-2-ol (1:3)	Aqueous Phase (%w/w)/ composition
B	25	45	30/salbutamol sulphate (17% w/v)
C	35	45	20/salbutamol sulphate (17% w/v)
D	40	40	20/salbutamol sulphate:lactose (70:30)(17%w/v)

5. The size of the resulting particles formed from each formulation was measured by photon correlation spectroscopy employing the Coulter N4 machine in the above described procedure. The results are given in Table II below.

Table II

Formulation	Nanoparticle size by PCS (scattering intensity) (mean \pm sd, n=7)
B	Population 1 (50.4%): 216 ± 43 nm Population 2 (49.6%): 40 ± 15 nm
C	34 ± 17 nm
D	69 ± 39 nm

10

A scanning electron micrograph of the salbutamol sulphate nanoparticles resulting from Formulation B was measured using the procedure described above. Figure 4 is a representation of the resulting scanning electron micrograph. The particles shown in Figure 4 appear spherical and generally less than 100nm in size in keeping with the

15 measurements given in Table II.

Example 3

Each of the nanoparticles resulting from the ternary formulations of Example 2 was employed to produce an aerosol composition.

- 5 In each case ~30mg of nanoparticles were dispersed in 0.5g n-hexane with 3 minutes sonication in a plastic vial for use in a pressurised metered dose inhaler. A Bepak BK 357 100µL metering valve was crimped in place and hydrofluoroalkane propellant (14g HFA-227) was added using a pressure burette. The valve was actuated through a mouthpiece with a 0.25mm orifice.

10

Visual evaluation of the compositions was performed prior and subsequent to sonication and at later time points to assess formulation stability and homogeneity.

- 15 The aerosol performance of each resulting nanoparticle HFA formulations was assessed by cascade impaction. The plates of an Andersen cascade impactor were coated with polyethylene glycol (molecular weight 300) to reduce particle bounce and re-entrainment.

- 20 In each case the pressurised metered dose inhaler was primed by firing five shots to waste and then 20 actuations were introduced into the Andersen cascade impactor, operating at 28.3 L min⁻¹, via a BP two-stage liquid impinger inlet. The actuator, inlet, impactor stages and filter were washed with 10 mL solution of a 50% ethanol/50% water mixture by sonication in a polythene bag.

- 25 Each washing was assayed for salbutamol sulphate concentration by HLPC-UV according to the procedure described above.

- 30 The results in terms of fine particle fraction, mass median aerodynamic diameter (MMAD) and geometric standard deviations (GSD) of the aerosols produced are given in Table III below. Three batches of each nanoparticle were employed to give the present results (mean ± sd, n=5).

Table III

Formulation	Fine Particle Fraction (<i>ex</i> device, <5.8 μ m)(%)	MMAD (μ m)	GSD (μ m)
B	58.3 \pm 6.8	1.2 \pm 0.4	2.3 \pm 1.1
C	65.5 \pm 5.1	1.3 \pm 0.2	2.3 \pm 0.3
D	59.0 \pm 4.6	1.5 \pm 0.6	1.9 \pm 0.8
Model	88.0 \pm 8	1.14 \pm 0.03	2.12 \pm 0.05

- 5 Included in Table III are equivalent data for a model solution system comprising a mixture of 30mg hexyl biphenylacetate, 0.5g n-hexane and 14g HFA-227. The data with respect to nanoparticles of the present invention are comparable to that of the model system. The model system represents the optimum that could be achieved with the present apparatus.
- 10 The fine particle fraction is the fraction likely to get into the lungs. The fine particle fraction for each of formulation B, C and D compares well to that achieved using the model solution.

The MMAD is an indication of the potential deposition site in the lungs. For each of
 15 formulations B, C and D, as well as the model system, the relatively low MMAD recorded suggests deep lung deposition.

The GSD is an indication of the polydispersity of the aerosols produced.

- 20 The combination of high fine particle fraction and low MMAD indicates very good performance of the aerosols. The present data suggests that in use a high fraction of nanoparticles would be deposited within the lung with the deposition being mainly alveolar.
- 25 Each of formulations B, C and D comprising nanoparticles produced from the lecithin-based microemulsion and the HFA-227:hexane blend could, on visual evaluation in the

plastic vial of the metered dose inhaler, be seen to be in the form of a stable dispersion. Each formulation appeared as a very fine homogeneous dispersion. The presence of a dispersion suggests that some flocculation of the nanoparticles within the hexane/HFA blend had occurred. By contrast, the nanoparticles on dispersion in n-hexane alone
5 produced an optically clear system.

No sedimentation or creaming of the flocculation in the HFA-227/n-hexane blend was observed over several months. The absence of sedimentation and creaming suggests that the flocculated particles must have been less than 1µm in size, and is desirable in order to
10 ensure reproducible dosing.

The flocculation in the HFA-227/hexane system was removed on aerosolisation, as can be seen from the results recorded in Table III for formulations B, C and D, relative to the model system.

15

By comparison, it proved impossible to disperse the product of Example 1 above in an HFA propellant. Even with the inclusion of a co-solvent for the AOT/iso-octane at a level of up to 10%w/w the nanoparticles aggregated and adsorbed on the wall of the pressurised metered dose inhaler vial.

20

Example 4

Nanoparticles were formed using the lecithin:propanol-2-ol 1:3 by weight surfactant system of Example 2 including as the active material pEGFP-N1 reporter plasmid DNA (4700 base pairs). The particles also contained protamine sulphate (1:1 by weight with
25 respect to pDNA) and sucrose at a concentration of 0.5M in the aqueous phase.

Nanoparticle formation was confirmed by photon correlation spectroscopy.

30

CLAIMS

1. Particulate composition comprising particles wherein the said particles:

- 5 (a) include an active material and, with respect to the total weight of the particles, more than 2 wt% of a surfactant material;
- (b) have an average diameter of more than about 1 nm and less than about 1000 nm;
- 10 (c) are spheroidal or spherical in shape; and
- (d) contain no cross-linked polymer formed from a monomer or preformed polymer with a cross-linking agent and initiator.

15

2. Particulate composition according to claim 1 wherein the particles comprise a core material including the active material and a coating on the core material comprising the surfactant material.

20 3. Particulate composition according to claim 2 wherein the core material is hydrophilic.

4. Particulate composition according to claim 2 wherein the core material is hydrophobic.

25

5. Particulate composition according to any one of the preceding claims wherein the particles have an average diameter of more than about 1 nm, preferably within the range of from about 10 nm to about 800 nm, even more preferably within the range of from about 20 nm to about 400 nm.

30

6. Particulate composition according to any one of the preceding claims wherein the particles comprise, with respect to the total weight of the said particles, up to about 90 wt% surfactant material, preferably up to about 60 wt% surfactant material.

7. Particulate composition according to any one of the preceding claims wherein the surfactant is selected from the group comprising emulsifiers, ionic, nonionic, zwitterionic, amphoteric surfactants and mixtures thereof.

5

8. Particulate composition according to any one of the preceding claims wherein the surfactant material is selected from the group comprising phospholipids, sorbitan esters, poloxamers, polyoxyethylene sorbitan esters, polyoxyethylene esters, bile salts, sodium bis (2 ethylhexyl) sulphosuccinate and mixtures thereof.

10

9. Particulate composition according to any one of the preceding claims wherein the active material comprises a medicament.

10. Particulate composition according to claim 9 wherein the medicament is selected
15 from the group comprising salbutamol, salbutamol sulphate, terbutaline, terbutaline sulphate, ipratropium bromide or any physiologically acceptable salts or solvates thereof; beclomethasone dipropionate, budesonide, triamcinolone acetonide or any physiologically acceptable solvates thereof; corticosteroid, bronchodilator; peptides, proteins, nucleic acids or derivatives thereof; insulin, calcitonin, growth hormone, lutenising hormone releasing
20 hormone, leuprolide, oxytocin or any physiologically acceptable salts or solvates thereof; or any mixture thereof.

11. Particulate composition according to any one of the preceding claims wherein the particles further comprise a polymeric material, preferably having a molecular weight
25 between 250 and 10×10^6 daltons.

12. Particulate composition according to claim 11 wherein the weight ratio of active material to polymeric material lies within the range of from about 99:1 to about 1:99.

30 13. Particulate composition according to any one of the preceding claims wherein the particles further comprise a sugar, preferably a mono and/or a disaccharide.

14. Particulate composition according to claim 13 wherein the weight ratio of active material to sugar lies within the range of from about 99:1 to about 1:99.

15. Particulate composition according to any one of the preceding claims wherein the particles further comprise a cationic lipid, preferably 1,2-dioleoyl-3-trimethylammonium propane.

16. Particulate composition according to any one of the preceding claims wherein the particles include nucleic acid precondensed with polycationic peptide, preferably protamine sulphate.

17. A method for preparing a particulate composition comprising particles having an average diameter within the range of from about 1 nm to less than about 1000 nm, wherein the method comprises:

(i) forming a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material;

(ii) forming a microemulsion by admixing the colloidal system of step (i) with a solution of an active material dissolved in a solvent, wherein the solution forms a disperse phase within the micelles of surfactant material;

(iii) quenching at least the disperse phase to a solid state; and

(iv) removing the continuous phase and the solvent so as to yield the said particles.

18. A method according to claim 17 wherein step (iii) includes snap freezing the continuous phase and the disperse phase.

19. A method according to claim 18 wherein the snap freezing occurs in liquid nitrogen.

20. A method according to claim 18 or claim 19 wherein the continuous phase and the solvent are removed by freeze-drying.

21. A method according to claim 17 wherein steps (iii) and (iv) include quenching the
5 disperse phase to a temperature higher than the freezing point of the continuous phase, separating the solidified disperse phase and the continuous phase, and removing by freeze drying the solvent from the disperse phase.

22. A method according to claim 21 wherein the solidified disperse phase is separated
10 from the continuous phase by centrifugation or ultrafiltration.

23. A method according to any one of claims 17 to 22 wherein the continuous phase is an apolar liquid and the solvent is water.

15 24. A method according to claim 23 wherein the apolar liquid is a hydrocarbon.

25. A method according to claim 24 wherein the hydrocarbon is selected from the group comprising *iso*-octane, octane, heptane, hexane, cyclohexane, benzene and mixtures thereof.

20

26. A method according to any one of claims 17 to 22 wherein the solvent comprises a lipophilic compound-solubilising liquid or a liquid miscible with a lipophilic compound, and the continuous phase comprises a liquid immiscible with the solvent, preferably the continuous phase is aqueous based.

25

27. A method according to any one of claims 17 to 26 wherein the surfactant material is selected from the group comprising emulsifiers, anionic, cationic, nonionic, zwitterionic, amphoteric surfactants and mixtures thereof.

30 28. A method according to claim 27 wherein the surfactant material is selected from the group comprising phospholipids, sorbitan esters, poloxamers, polyoxyethylene sorbitan esters, polyoxyethylene esters, sodium bis (2-ethylhexyl) sulphosuccinate, bile salts and mixtures thereof.

29. A method according to any one of claims 17 to 28 wherein the colloidal system formed in step (i) comprises a weight ratio of continuous phase to surfactant material within the range of from about 10,000:1 to about 30:70, preferably within the range of
5 from about 100:1 to about 40:60.

30. A method according to any one of claims 17 to 29 wherein the solution of active material of step (ii) is at a concentration of about 2,000 to about 0.1 $\mu\text{g/g}$ active material in the solvent.

10

31. A method according to any one of claims 17 to 30 wherein the colloidal system of step (i) is admixed with the solution of step (ii) at a weight ratio of colloidal system to solution within the range of from about 45:55 to about 100:1, preferably within the range of from about 60:40 to about 95:5.

15

32. A method according to any one of claims 17 to 31 wherein the solution of step (ii) includes dissolved material additional to the said active material.

33. A method according to claim 32 wherein the additional dissolved material is
20 selected from the group comprising polymeric materials, sugars, cationic lipids, peptides and mixtures thereof.

34. A method according to claim 32 or claim 33 wherein the additional material is contained in the solution at a concentration of about 2,000 to about 0.1 mg/g , preferably at
25 a concentration of about 1,500 to about 10 mg/g , with respect to the solvent.

35. A method according to any one of claims 17 to 34 wherein the active material is a medicament.

30 36. A method according to claim 35 wherein the medicament is selected from the group comprising salbutamol, salbutamol sulphate, terbutaline, terbutaline sulphate, ipratropium bromide or any physiologically acceptable salts or solvates thereof; beclomethasone dipropionate, budesonide, triamcinolone acetonide or any physiologically

acceptable solvates thereof; corticosteroid, bronchodilator; peptides, proteins, nucleic acids or derivatives thereof; insulin, calcitonin, growth hormone, lutenising hormone releasing hormone, leuprolide, oxytocin or any physiologically acceptable salts or solvates thereof; or any mixture thereof.

5

37. A method according to any one of claims 17 to 36 for preparing the particulate composition according to claim 1.

38. An aerosol composition comprising a particulate composition according to any one
10 of claims 1 to 16 or as prepared by the method according to any one of claims 17 to 37, and a liquid aerosol propellant.

39. An aerosol composition according to claim 38 wherein the liquid propellant is selected from the group comprising hydrocarbons, hydrochlorocarbons, chlorocarbons,
15 hydrochlorofluorocarbons, chlorofluorocarbons, hydrofluorocarbons, fluorocarbons and mixtures thereof.

40. An aerosol composition according to claim 39 wherein the liquid propellant is a hydrofluoroalkane selected from the group comprising 1,1,1,2-tetrafluoroethane,
20 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

41. An aerosol composition according to any one of claims 38 to 40 wherein the aerosol composition has a weight ratio of propellant to particulate composition within the range of from about 10,000:1 to about 25:1, preferably from about 1,000:1 to about 100:1.
25

42. An aerosol composition according to any one of claims 38 to 41 provided in the form of a metered dose inhaler.

43. An aerosol composition according to any one of claims 38 to 42 in a form suitable
30 for oral inhalation, nasal and/or ocular administration.

44. An aerosol composition according to any one of claims 38 to 43 for use in the administration to the lung of a medicament to a patient in need thereof.

45. An aerosol composition according to claim 44 for use in the treatment of respiratory disease.

5 46. An aerosol composition according to claim 44 or claim 45 wherein the medicament, for example a nucleic acid, a peptide and/or a protein, is intended to be absorbed systemically by the patient.

10 47. A metered dose inhaler containing an aerosol composition according to any one of claims 38 to 46.

15 48. Use of the particulate composition according to any one of claims 1 to 17 or of the product of any one of claims 18 to 37 in the manufacture of an aerosol composition for lung delivery of a medicament for the treatment of, for example, a respiratory disorder in a patient.

20 49. A method of administering a particulate composition to a patient in need thereof comprising spraying the aerosol formed from the aerosol composition according to any one of claims 38 to 46 on to or towards the area intended to receive the particulate composition.

50. A method according to claim 49 wherein the patient inhales the aerosol.

1/3

FIG. 1





FIG. 2



2/3

FIG. 3

Lecithin:Propan-2-ol (1:3)




FIG. 4



3/3

FIG. 5





FIG. 6



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/78689 A3

(51) International Patent Classification⁷: A61K 9/51, 9/12

(21) International Application Number: PCT/GB01/01752

(22) International Filing Date: 18 April 2001 (18.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0009773.3 19 April 2000 (19.04.2000) GB

(71) Applicant (for all designated States except US): **UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED** [GB/GB]; P.O. Box 497, Cardiff CF1 3XR (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DICKINSON, Paul, Alfred** [GB/GB]; 6 Turnberry Close, Tytherington, Macclesfield SK10 2TQ (GB). **KELLAWAY, Ian, Walter** [GB/GB]; 1 Cyncoed Avenue, Cardiff CF23 6ST (GB). **HOWELLS, Stephen, Wyn** [GB/GB]; 61 Pentre Street, Grangetown, Cardiff CF11 6QX (GB).

(74) Agents: **HOWARD, Paul, Nicholas et al.**; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
28 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PARTICULATE COMPOSITION



(57) Abstract: Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with the micelles of surfactant material. At least the dispersed phase is quenched to a solid state and the continuous phase and solvent are removed to produce the nanoparticles. The nanoparticles can be incorporated in an aerosol composition suitable for deep lung delivery by means of a metered dose inhaler.

WO 01/78689 A3

INTERNATIONAL SEARCH REPORT

Intr national Application No
PC1/GB 01/01752

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/51 A61K9/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE, LIFESCIENCES, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 20041 A (NOVO NORDISK BIOTECH INC) 5 June 1997 (1997-06-05) page 7, line 15 - line 20 ---	1-10
X	DATABASE WPI Section Ch, Week 198915 Derwent Publications Ltd., London, GB; Class B05, AN 1989-110408 XP002182211 -& JP 01 056136 A (NIPPON KAYAKU KK), 3 March 1989 (1989-03-03) abstract ---	1-9, 17, 26-28, 32, 34, 35, 37
X	EP 0 526 666 A (GASCO MARIA ROSA) 10 February 1993 (1993-02-10) cited in the application example 1 claim 7 ---	1-10
	--- -/--	

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

9 November 2001

Date of mailing of the international search report

20/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

International Application No

PC 1/GB 01/01752

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 091 188 A (HAYNES DUNCAN H) 25 February 1992 (1992-02-25) page 10, line 18 - line 20 example 6 claims 1,11,15 ----	1-9, 38, 47-49
X	EP 0 877 033 A (SAHOO SANJEEB KUMAR ;GHOSH P K (IN); K TAPAS DE (IN); MAITRA AMARN) 11 November 1998 (1998-11-11) cited in the application column 3, line 21 - line 40 figure 2; examples 1,3 ----	1-12
A	"Publications 1999" WELSH SCHOOL OF PHARMACY, 'Online! 1999, XP002182392 Retrieved from the Internet: <URL:http://www.cf.ac.uk/research/pubs99/p hrmy.html> 'retrieved on 2001-11-09! page 3 see references of Howells SW et al. -----	17
A		1,17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/GB 01/01752

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9720041	A	05-06-1997	US 5693516 A	02-12-1997
			AU 1126597 A	19-06-1997
			CA 2238568 A1	05-06-1997
			EP 0871714 A1	21-10-1998
			JP 2000502060 T	22-02-2000
			WO 9720041 A1	05-06-1997
			US 5756331 A	26-05-1998
JP 1056136	A	03-03-1989	JP 2047293 C	25-04-1996
			JP 7073668 B	09-08-1995
EP 0526666	A	10-02-1993	EP 0526666 A1	10-02-1993
			AT 136774 T	15-05-1996
			DE 69118880 D1	23-05-1996
			DE 69118880 T2	07-11-1996
			ES 2089066 T3	01-10-1996
			US 5250236 A	05-10-1993
US 5091188	A	25-02-1992	AT 181234 T	15-07-1999
			AU 7852891 A	11-11-1991
			CA 2078990 A1	27-10-1991
			DE 69131349 D1	22-07-1999
			DE 69131349 T2	18-11-1999
			DK 533690 T3	22-11-1999
			EP 0533690 A1	31-03-1993
			ES 2134776 T3	16-10-1999
			GR 3030825 T3	30-11-1999
			IN 173056 A1	05-02-1994
			KR 159114 B1	01-12-1998
			MX 25532 A	01-10-1993
			RU 2100030 C1	27-12-1997
			WO 9116068 A1	31-10-1991
			US RE35338 E	24-09-1996
			US 5091187 A	25-02-1992
			US 5246707 A	21-09-1993
			ZA 9103122 A	29-04-1992
EP 0877033	A	11-11-1998	EP 0877033 A1	11-11-1998

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)